Prophylactic Antiemetics for Haematological Malignancies: Prospective Nationwide Survey Subset Analysis in Japan
| Autor: | Kyoya Kumagai, Tsutomu Takahashi, Moritaka Gotoh, Yasuhito Nanya, Toshihiro Miyamoto, Mototsugu Shimokawa, Yasushi Takamatsu, Itaru Matsumura, Naoki Kurita, Kiyohiko Hatake, Isao Yoshida, Keisuke Aiba, Kenichi Ishizawa, Noriko Usui, Kazuo Tamura, Tadahiko Igarashi |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male Cancer Research Vincristine medicine.medical_specialty Cyclophosphamide Vomiting Nausea Premedication medicine.medical_treatment CHOP Severity of Illness Index General Biochemistry Genetics and Molecular Biology 03 medical and health sciences 0302 clinical medicine Japan Prednisone Surveys and Questionnaires Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Risk factor Aged Pharmacology Chemotherapy business.industry Incidence Middle Aged Treatment Outcome Health Care Surveys Hematologic Neoplasms 030220 oncology & carcinogenesis Antiemetics Antiemetic chemotherapy-induced nausea and vomiting CHOP therapy haematological malignancies Female medicine.symptom business Research Article medicine.drug |
| Zdroj: | In Vivo. 33:1355-1362 |
| ISSN: | 1791-7549 0258-851X |
| DOI: | 10.21873/invivo.11611 |
| Popis: | Background/aim Although neurokinin-1 receptor antagonists are approved chemotherapy drugs in Japan, no nationwide surveys have been performed to validate chemotherapy-induced nausea and vomiting (CINV) guidelines in clinical practice. This study evaluated CINV in patients with haematological malignancies starting first-time chemotherapy. Patients and methods A nationwide CINV survey on patients with haematological malignancies was conducted at 118 institutions. Patients undergoing moderately emetic chemotherapy (n=17) and highly emetic chemotherapy (HEC; n=180) were compared. Results Forty-one patients undergoing HEC received triple antiemetics. Female gender and young age were risk factors for early-phase nausea, while female gender remained a risk factor for late-phase nausea and vomiting. Among 125 patients receiving CHOP (doxorubicin, cyclophosphamide, vincristine, prednisone)-like regimens, complete response and complete control were increased in patients receiving triple antiemetics, compared to those with double antiemetics. Conclusion Guideline compliance was very low. Although not statistically significant, there was a trend for reduced CINV and improved disease control for triple versus double antiemetics, suggesting that triple antiemetics should be considered for HEC, especially in young female patients with non-Hodgkin lymphoma receiving CHOP-like regimens. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|